In this free webinar, oncology experts will discuss what ASCO 2026 data could mean for cancer clinical trials and patient ...

Earlier this year, Daiichi Sankyo Global Head of Oncology Ken Keller told pharmaphorum about the company’s big year, with ...

Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01.

These results support darovasertib plus Xalkori as a potential new standard of care if approved for HLA A*02:01-negative ...

Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).

The American Society of Clinical Oncology 2026 annual meeting showcased how, across tumour types, new cancer therapies are achieving deeper responses, extending survival and increasingly moving ...

At the upcoming 2026 ASCO meeting, Elizabeth A. Sakach, MD, expects the focus in metastatic breast cancer will be on the frontline integration of antibody-drug conjugates (ADCs) in triple-negative ...

Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is ...

At ASCO 2026, in early-stage hormone receptor-positive breast cancer, the phase 3 OPTIMA trial evaluated molecular risk-guided chemotherapy decision-making in the context of optimized endocrine ...

Integrated analyses show higher tumor exposure than doxorubicin and better preservation of cardiac function in randomized soft tissue sarcoma studies despite approximately 3.5-fold higher cumulative ...

As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial edge.